Montelukast Added to Standard Therapy for Acute Asthma in Children Age 6-14 Years

Stopped early · Not applicable

Conditions studied: Asthma

In brief

Oral montelukast is helpful in chronic asthma. The purpose of this pediatric study was to investigate whether the addition of oral montelukast to standard therapy for acute asthma exacerbations results in further improvement in breathing function over three hours.

Key facts

Study ID

NCT00353184

Run by

Washington University School of Medicine

People needed

27

Starts

2001-09-01

Expected to finish

2005-02-01

Last updated by the study team

2010-02-24

Who can join

Age: 6 and older, up to 14. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Seeking care in ED for acute asthma exacerbation
• Age 6-14 years inclusive
• Initial FEV1 = 40-70% predicted (defined as moderate severity)
• Consent to participate in study

You may not qualify if…

• Severe exacerbation requiring immediate therapy as determined by treating clinician
• Pregnancy by history
• Cystic Fibrosis by history
• Tuberculosis
• Gastroesophageal reflux disease requiring medications
• Acute or chronic liver disease
• Bronchopulmonary dysplasia
• Premature <34 weeks gestational age by history
• Having used leukotriene-modifying medication within 48 hours
• Having used theophylline within four weeks
• Unable to perform FEV1

Where it is running

• St. Louis Children's Hospital — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.